Dr. Fisher on Bortezomib/R-CHOP Combo for Mantle Cell Lymphoma
In Partnership With:
Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.
Richard Fisher, MD, president and CEO of Fox Chase Cancer Center, discusses adding bortezomib (Velcade) to the standard R-CHOP regiment (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone) for previously untreated mantle cell lymphoma.
A phase 2 study of this combination showed promising results. While the level of toxicities were minimal during the trial, there were some cases of neurotoxicity.
Fisher says that the results of the trial show the potential of bortezomib as a treatment option for patients with mantle cell lymphoma.
